Molecular Weight(MW): 343.42
SB525334 is a potent and selective inhibitor of TGFβ receptor I (ALK5) with IC50 of 14.3 nM in a cell-free assay, 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.
Cited by 12 Publications
8 Customer Reviews
Immunoprecipitation and immunoblotting of wild-type cells treated as indicated (n = 3 experiments). i=TGFβR inhibitor:SB525334.
Nature, 2017, 551(7678):105-109. SB525334 purchased from Selleck.
Increased dietary salt intake activates the Smad2 signaling pathway to promote a decrease in endothelial PTEN levels, phosphorylation of Akt at S473, and phosphorylation of NOS3 at S1177. The TβRI/ALK5 kinase inhibitor, SB525334, prevented the salt-induced increases in Smad2 phosphorylation and the downstream signaling events that included the reduction in PTEN levels and increases in phosphorylated Akt(S473) and phosphorylated NOS3(S1177). The graphs on the right represented the pertinent relative protein levels of all the animals in the study (n = 6 rats in each group). *P < 0.05 compared to the other 3 groups.
Hypertension 2013 62(5), 951-6. SB525334 purchased from Selleck.
LS 174T and SW480 cells were treated with SB525334 (1 umol/L) for 12 hours. HMGA2 expression was assessed by immunoblotting. Each experiment was repeated 3 times. Bars, SD; *, P < 0.05; **, P < 0.01.
Cancer Lett 2014 355(1), 130-40. SB525334 purchased from Selleck.
(A) The cellular appearances of EMT were observed in Bel7402-siAZGP1 and controls pretreated with SB525334 (inhibitor of TGF-β1/ALK5), LY364947 (inhibitor of TGF-β1/2), PD98059 (inhibitor of ERK) and DMSO. (B, C) CDH1 (E-cadherin) and Vim (Vimentin) mRNA were detected in 8 groups (**compared with controls pretreated with DMSO, p < 0.001; ##compared with controls pretreated with LY364947, p < 0.001).
Cancer Lett, 2016, 374(2):241-9. SB525334 purchased from Selleck.
Blocking of TGF signaling results in severe BD paucity in hilum region and loss of BECs in periphery region. (a-b’) At E18.5, α-SMA (red) was detected in the PVM. Near to -SMA positive cells, BECs labeled with CK19 (green) form a bile duct (a,a’, arrows) in the hilum region or a single layer of CK19 positive cells that resembled the primitive ductal plate (b,b’, arrows) in the periphery region, respectively. (c-d’) In contrast, in SB525334 treated liver, CK19+ cells had not yet formed bile ducts in hilum of the liver tissues (c,c’, arrows) and showed significantly decrease of CK19 positive BECs in periphery region (d,d’, arrows). (e,f) The total number of bile ducts in hilum and CK-19 positive BECs in periphery were counted in per high power field. At least four images of portal fields for each animal were analysed (n = 4 animals treatment of SB525334; n = 4 controls). Bars represent mean ± standard error of the mean. *p < 0.05. Nuclei were stained with DAPI (blue). bd, bile duct; bec, biliary epithelial cell; pdp, primitive ductal plate; pv, portal vein. Scale bars: 100mm in a,b,c,d; 20mm in a’,b’,c’,d’
J Cell Physiol, 2018, 233(8):5780-5791. SB525334 purchased from Selleck.
Ang-(1-7) appears to inhibit MGA-induced fluorescent staining for de novo expression of α-SMA in NRK 52-E cells. Cells were incubated with serum free media (A and C) or MGA (100 uM, B, D-I) or TGF-β (5 ng, J) for 72 h. MGA-treated cells were treated with either Ang-(1-7) (100 nM, E), Ang-(1-7) and DAL (10 uM, F), ERK1/2 inhibitor PD98059 (1 uM, G), TGF-β receptor kinase inhibitor SB525334 (1 uM, H) or AT1 receptor antagonist losartan (1 uM, I). The immunofluorescent images are representative of 3 different cell passages.
Cell Signal 2014 10.1016/j.cellsig.2014.09.010. SB525334 purchased from Selleck.
The effect of ERK1/2 and Smad2/3 signaling pathway inhibition by SB525334 on the TGF-β1-stimulated expression of TIMP-3. Chondrocytes were pretreated with the TGF-β1 receptor I (ALK5) kinase inhibitor SB525334 (1 uM) for 60 min followed by stimulation with or without TGF-β1 (10 ng/ml) for 48 h. TIMP-3 protein levels, as evaluated by Western blotting.
Cell Signal 2014 10.1016/j.cellsig.2014.09.010. SB525334 purchased from Selleck.(C) C3H10T1/2 cells transfected with pEF-BOS or pEF-Flag-TAZ were cultured for 8 days in osteogenic medium (OM) including ascorbic acid and β-glycerophosphate in the absence or presence of TGF-β inhibitors (SB-431542 or SB-525334). ALP activity was measured in the cell layer and normalized to cellular protein content. Data are expressed as means 6 ± SD ( *p < 0.05 vs. pEF-BOS, # p < 0.01 vs. vehicle) (D) Quantitative RT-PCR analysis of Col 1 and ALP in C3H10T1/2 cells.
SB525334 purchased from Selleck.
Purity & Quality Control
Choose Selective TGF-beta/Smad Inhibitors
|Description||SB525334 is a potent and selective inhibitor of TGFβ receptor I (ALK5) with IC50 of 14.3 nM in a cell-free assay, 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.|
SB 525334 shows no inhibition in the enzymes ALK2, 3, and 6, with IC50 values > 10 μM. SB 525334 blocks phosphorylation induced by TGF-β1 and nuclear translocation of Smad2/3 in renal proximal tubule cells. SB 525334 also inhibits the increased mRNA expression levels of plasminogen activator inhibitor-1 (PAI-1) and procollagen α1(I) induced by TGF-β1 in A498 renal epithelial carcinoma cells at 1 μM).  SB 525334 (1 μM) attenuates the heightened sensitivity to TGF-β1 exhibited by pulmonary artery smooth muscle cells (PASMCs) from patients with familial forms of idiopathic pulmonary arterial hypertension (PAH). 
|In vivo||SB 525334 (10 mg/kg/day) decreases the renal mRNA levels of PAI-1, procollagen α1(I), and procollagen α1(III) in a nephritis-induced renal fibrosis rat model. Furthermore, PAN-induced proteinuria is significantly inhibited by SB 525334 (10 mg/kg/day).  SB 525334 may also be efficacious in mesenchymal tumors. SB 525334 (10 mg/kg/day) significantly decreases uterine mesenchymal tumor incidence, multiplicity, and size in Eker rats.  SB 525334 significantly reverses pulmonary arterial pressure and inhibits right ventricular hypertrophy in a rat model of PAH. This is revealed by a significant reduction in pulmonary arteriole muscularization induced by monocrotaline (used to induce PAH) after treatment with SB 525334 (3 or 30 mg/kg).  In a Bleomycin-induced pulmonary fibrosis mice model, SB 525334 (10 mg/kg or 30 mg/kg) attenuates the histopathological alterations in the lung, and significantly decreased mRNA expression of Type I and III procollagen and fibronectin. SB 525334 also attenuates Smad2/3 nuclear translocation, myofibroblast proliferation, deposition of Type I collagen, and decreases CTGF-expressing cells. |
Kinase assay to determine the potency and selectivity of SB 525334:In order to determine the potency of SB 525334, purified GST-tagged kinase domain of ALK5 is incubated with purified GST-tagged full-length Smad3 in the presence of 33P-γATP and different concentrations of SB 525334. The readout is radioactively labeled Smad3. To determine the selectivity of SB 525334, purified GST-tagged kinase domain of ALK2 and ALK4 are incubated with GST-tagged full-length Smad1 and Smad3, respectively, in the presence of different concentrations of SB 525334. IC50 values are calculated.
|In vitro||DMSO||68 mg/mL (198.0 mM)|
|Ethanol||68 mg/mL (198.0 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
I want to know the feasibility of using the compound via oral gavage in rodents (dosing, frequency, formulation…)?
Our S1476 can be used for oral gavage in rodents, and the vehicle we suggest is: 30% Propylene glycol, 5% Tween 80, 65% D5W (dextrose(5%)in water) at 20mg/ml maximum. Based on the following reference they administrated it at an estimated dose of 10 mg/kg/day in rat for 2 months: http://clincancerres.aacrjournals.org/content/13/10/3087.long